Evidence map›Paper›PMID 36243854›Full record

ReviewCurrent topics in microbiology and immunology2022

PI3K Targeting in Non-solid Cancer.

Hye Na Kim, Heather Ogana, Vanessa Sanchez, Cydney Nichols, Yong-Mi Kim

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current topics in microbiology and immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hye Na KimDepartment of Pediatrics, Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA.
Heather OganaDepartment of Pediatrics, Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA.
Vanessa SanchezDepartment of Pediatrics, Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA.
Cydney NicholsDepartment of Pediatrics, Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA.
Yong-Mi KimDepartment of Pediatrics, Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA. ymkim@chla.usc.edu.
University of Southern California · USChildren's Hospital of Los Angeles · US

Funding

Understanding the niche of minimal residual disease leukemia cellsR01CA172896 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KIM, YONG-MI · 2013 to 2022
$3.7M
USC/CHLA Summer Oncology Research Fellowship (SORF) Program for Medical StudentsR25CA225513 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI ANAT ERDREICH-EPSTEIN, WIJBE MARTIN KAST · 2019 to 2026
$1.7M
NCI NIH HHS R01 CA172896NCI NIH HHS R25 CA225513
6 · The paper itself

Abstract

Despite the therapeutic progress, relapse remains a major problem in the treatment of acute lymphoblastic leukemia (ALL). Most leukemia cells that survive chemotherapy are found in the bone marrow (BM), thus resistance to chemotherapy and other treatments may be partially attributed to pro-survival signaling to leukemic cells mediated by leukemia cell-microenvironment interactions. Adhesion of leukemia cells to BM stromal cells may lead to cell adhesion-mediated drug resistance (CAM-DR) mediating intracellular signaling changes that support survival of leukemia cells. In ALL and chronic lymphocytic leukemia (CLL), adhesion-mediated activation of the PI3K/AKT signaling pathway has been shown to be critical in CAM-DR. PI3K targeting inhibitors have been approved for CLL and have been evaluated preclinically in ALL. However, PI3K inhibition has yet to be approved for clinical use in ALL. Here, we review the role of PI3K signaling for normal hematopoietic and leukemia cells and summarize preclinical inhibitors of PI3K in ALL.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellMesenchymal Stem CellsHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTumor MicroenvironmentPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAcute lymphoblastic leukemia (ALL)Cell adhesion mediated drug resistance (CAM-DR)PI3K/AKTPI3KγPI3Kδ

Identifiers

PMID36243854
PMCPMC10075235
OpenAlexW4306362015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.